A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Completed · Phase 3 · Has a placebo group

Conditions studied: Esophageal Squamous Cell Carcinoma (ESCC)

In brief

The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

Key facts

Study ID
NCT03783442
Run by
BeiGene
People needed
649
Starts
2018-12-11
Expected to finish
2024-08-22
Last updated by the study team
2025-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.